4530 HISAMITSU PHARMACEUTICAL CO.,INC. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4530

TSE Prime

HISAMITSU PHARMACEUTICAL CO.,INC.

6,366

JPY

+16

(+0.25%)

Jan 29, 3:30 pm JST

41.62

USD

Jan 29, 1:30 am EST

Result

ー

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Feb, 2022	120,193	9,337	12,638	9,658	118.9	84	Apr 7, 2022	J-GAAP
Feb, 2023	128,330	11,599	16,051	11,742	148.0	84.50	Apr 13, 2023	J-GAAP
Feb, 2024	141,706	13,167	19,649	13,969	181.6	85	Apr 11, 2024	J-GAAP
Feb, 2025	156,006	18,895	24,010	21,758	295.6	90	Apr 10, 2025	J-GAAP
Feb, 2026 Guidance	ー	ー	ー	ー	－	60	Jan 6, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Feb, 2021	Apr 10, 2020	ー	ー	ー	ー	－	J-GAAP
- - - - -	Jul 9, 2020	127,000	12,900	14,800	10,600	83.5	J-GAAP
	Mar 23, 2021	115,000	10,600	11,900	9,300	83.5	J-GAAP
Results	Apr 8, 2021	114,510	10,671	11,829	9,250	83.5	J-GAAP
Feb, 2022	Apr 8, 2021	Available in future release
	Mar 23, 2022
Results	Apr 7, 2022
Feb, 2023	Apr 7, 2022
	Mar 30, 2023
Results	Apr 13, 2023
Feb, 2024	Apr 13, 2023
	Jan 11, 2024
Results	Apr 11, 2024
Feb, 2025	Apr 11, 2024
	Jan 9, 2025
Results	Apr 10, 2025
Feb, 2026	Apr 10, 2025	165,000	20,000	24,300	22,000	120	J-GAAP
- - - -	Jan 6, 2026	ー	ー	ー	ー	60	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Feb, 2001	65,240	+19.4	Available in future release
Feb, 2002	69,538	+6.6
Feb, 2003	70,000	+0.7
Feb, 2004	74,588	+6.6
Feb, 2005	83,545	+12.0
Feb, 2006	102,665	+22.9
Feb, 2007	109,791	+6.9
Feb, 2008	119,061	+8.4
Feb, 2009	124,655	+4.7
Feb, 2010	129,834	+4.2
Feb, 2011	137,184	+5.7
Feb, 2012	137,794	+0.4
Feb, 2013	142,772	+3.6
Feb, 2014	150,635	+5.5
Feb, 2015	156,743	+4.1
Feb, 2016	161,852	+3.3
Feb, 2017	145,925	-9.8
Feb, 2018	148,466	+1.7
Feb, 2019	143,408	-3.4
Feb, 2020	140,992	-1.7
Feb, 2021	114,510	-18.8
Feb, 2022	120,193	+5.0
Feb, 2023	128,330	+6.8
Feb, 2024	141,706	+10.4
Feb, 2025	156,006	+10.1
Feb, 2026 Guidance	ー	-100.0	ー	-100.0	ー	-100.0	－	-100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Feb, 2024	141,706	13,167	9.29	5.37	4.35	0.44	181.6
Feb, 2025	156,006	18,895	12.1	8.04	6.48	0.46	295.6
Feb, 2026 Guidance	ー	ー	ー	ー	ー	ー	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	161,852	32,532	33,494	21,758	295.6
Fiscal Year	Feb, 2016	Feb, 2009	Feb, 2012	Feb, 2025	Feb, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2022	68,711	6,686	7,181	5,238	66.0	42.25	Apr 13, 2023	J-GAAP
Sep - Feb, 2023	74,729	4,771	8,009	5,552	72.2	42.50	Apr 11, 2024	J-GAAP
Sep - Feb, 2024	80,550	9,889	13,222	12,660	172.0	45	Apr 10, 2025	J-GAAP
Sep - Feb, 2025 Guidance	ー	ー	ー	ー	－	0	Jan 6, 2026	J-GAAP
YoY	－	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Feb, 2023	11,599	-11,141	12,727	-23,868	-14,687	65,424	20.84	J-GAAP
Feb, 2024	13,167	15,676	18,188	-2,512	-16,691	66,366	20.19	J-GAAP
Feb, 2025	18,895	36,328	18,765	17,563	-15,850	89,780	26.17	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Mar - Nov, 2023	102,827	12,246	16,638	12,092	156.4	84.7	Jan 11, 2024	J-GAAP
Mar - Nov, 2024	111,253	13,220	16,471	13,660	185.0	68.6	Jan 9, 2025	J-GAAP
Mar - Nov, 2025	114,514	12,608	16,630	11,890	165.8	ー	Jan 6, 2026	J-GAAP
YoY	+2.9%	-4.6%	+1.0%	-13.0%	-10.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Dec - Feb, 2023	38,879	921	3,011	1,877	24.4	2.4	Apr 11, 2024	J-GAAP
Mar - May, 2024	35,810	4,149	5,562	4,788	63.9	11.6	Jul 11, 2024	J-GAAP
Jun - Aug, 2024	39,646	4,857	5,226	4,310	58.1	12.3	Oct 10, 2024	J-GAAP
Sep - Nov, 2024	35,797	4,214	5,683	4,562	61.8	11.8	Jan 9, 2025	J-GAAP
Dec - Feb, 2024	44,753	5,675	7,539	8,098	110.0	12.7	Apr 10, 2025	J-GAAP
Mar - May, 2025	34,665	3,364	3,780	2,564	35.1	9.7	Jul 10, 2025	J-GAAP
Jun - Aug, 2025	40,278	4,764	6,309	4,458	61.6	11.8	Oct 9, 2025	J-GAAP
Sep - Nov, 2025	39,571	4,480	6,541	4,868	67.9	11.3	Jan 6, 2026	J-GAAP
YoY	+10.5%	+6.3%	+15.1%	+6.7%	+9.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec - Feb, 2020	33,688	-19.6	Available in future release
Mar - May, 2021	27,761	+11.6
Jun - Aug, 2021	30,790	+9.8
Sep - Nov, 2021	28,112	+0.8
Dec - Feb, 2021	33,530	-0.5
Mar - May, 2022	26,393	-4.9
Jun - Aug, 2022	33,226	+7.9
Sep - Nov, 2022	32,262	+14.8
Dec - Feb, 2022	36,449	+8.7
Mar - May, 2023	32,096	+21.6
Jun - Aug, 2023	34,881	+5.0
Sep - Nov, 2023	35,850	+11.1
Dec - Feb, 2023	38,879	+6.7
Mar - May, 2024	35,810	+11.6
Jun - Aug, 2024	39,646	+13.7
Sep - Nov, 2024	35,797	-0.1
Dec - Feb, 2024	44,753	+15.1
Mar - May, 2025	34,665	-3.2
Jun - Aug, 2025	40,278	+1.6
Sep - Nov, 2025	39,571	+10.5	4,480	+6.3	6,541	+15.1	67.9	+9.9

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	44,753	10,313	10,489	9,054	110.0
Fiscal Year	Feb, 2024	Nov, 2007	Nov, 2007	Nov, 2016	Feb, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Feb, 2023	3,294.20	81.6	313,917	256,105	235,569	0.01	Apr 13, 2023	J-GAAP
Feb, 2024	3,492.62	80.5	328,779	264,541	242,578	0.01	Apr 11, 2024	J-GAAP
Feb, 2025	3,788.47	80.6	343,068	276,417	257,881	0.01	Apr 10, 2025	J-GAAP
Mar - Nov, 2025	ー	78.5	342,309	268,560	223,384	0.01	Jan 6, 2026	J-GAAP

HISAMITSU PHARMACEUTICAL CO.,INC.(4530) Financial Results